Bio Green Med Solution, Inc. (BGMS)
NASDAQ: BGMS · Real-Time Price · USD
0.9400
+0.0396 (4.40%)
At close: May 12, 2026, 4:00 PM EDT
0.9800
+0.0400 (4.26%)
Pre-market: May 13, 2026, 4:14 AM EDT
Bio Green Med Solution Earnings Call Transcripts
Fiscal Year 2024
-
FADRA, a dual CDK2/9 inhibitor, is showing promising efficacy and safety in phase 2 trials for cancers with CDKN2A/B mutations and T-cell lymphoma, with durable responses and strong biomarker rationale. PLOGO, a PLK-1 inhibitor, is being reformulated for future trials targeting ARID1A or TP53 mutations.
-
Phase 2 enrollment for Fadraciclib is progressing, with initial data from about 12 patients expected by year-end 2024. Cash resources are projected to last into Q4 2024, and R&D expenses have decreased year-over-year.